Share on facebook Share on Twitter Share on Google Plus Share This

Burkitt Lymphoma

Lymphoma is a cancer of lymphocytes, which are white blood cells of the immune system that circulate in lymph nodes throughout the body and the spleen. Lymphoma is divided into two main subtypes: Hodgkin lymphoma (HL) and Non-Hodgkin Lymphoma (NHL). Within the category of Non-Hodgkin lymphoma, there are many different subtypes. Burkitt lymphoma is a rare subtype of Non-Hodgkin lymphoma and accounts for only ~1% of Non-Hodgkin lymphoma in adults.

There are three main types of Burkitt lymphoma: endemic, sporadic and immunosuppression-related. The endemic form is generally found in sub-Saharan Africa. This form usually presents in the jaw or as a facial bone tumor. The sporadic form usually presents with an intra-abdominal mass with symptoms of bowel obstruction or gastrointestinal bleeding. The immunodeficiency-related case involves lymph nodes and can be seen in connection with HIV infection or after organ transplantation.

Burkitt lymphoma can cause enlarged lymph nodes throughout the body as well as an enlarged liver and spleen. Burkitt lymphoma can affect the bone marrow and the circulating blood. In addition it also can affect the gastrointestinal tract and the brain.

Symptoms of Burkitt Lymphoma

Symptoms for Burkitt lymphoma can be enlarged lymph nodes and/or the spleen. Burkitt lymphoma can also cause fevers, chills, night sweats and unexplained weight loss (B-symptoms). Gastrointestinal symptoms can also be common.

Risk Factors for Burkitt Lymphoma

There are no known inherited predisposition to Burkitt lymphoma. In the endemic type of Burkitt lymphoma, there is a strong association with Epstein-Barr Virus (EBV )infection. In the immunodeficiency type of Burkitt lymphoma, there is a clear association with decreased function of the immune system to destroy early pre-cancerous cells.

How Burkitt Lymphoma is Diagnosed

The diagnosis is usually made by surgical removal of one of the enlarged lymph nodes. Since there are many other lymphomas that can resemble this disease and the treatments are different, it is important to carefully review the lymph node under the microscope. The diagnosis is confirmed by the presence of a certain genetic abnormality, an abnormal chromosome fusion that results in over-expression of the MYC protein in the lymphoma cells. FISH (fluorescence in-situ hybridization) is a test that can detect this chromosome abnormality in the lymphoma cells. Laboratory studies have shown that the MYC protein is responsible for promoting the survival and growth of the cancerous cells.

Once the diagnosis of Burkitt lymhompa is established, computed axial tomography (CAT) scans of the neck, chest, abdomen and pelvis are necessary to determine the degree and extent of involvement of the lymph nodes. A bone marrow biopsy is usually performed to determine the degree of involvement of the bone marrow. Together, these tests establish the clinical stage of the lymphoma.

Flow cytometry analysis of the lymphoma cells will determine whether the cancer cells express certain proteins on their surface that are characteristic of Burkitt lymphoma. Evaluation of the gastrointestinal system for lymphoma involvement is sometimes necessary requiring an endoscopy, particularly if the patient is having any gastrointestinal symptoms. Evaluation of heart function with an echocardiogram or Multiple Gated Acquisition (MUGA) scan can be necessary before treatment with chemotherapy drugs is considered since adriamycin, one of the main drugs used in treatment, can affect heart function at high doses. The brain can also be involved by lymphoma; therefore, it is necessary to sample the fluid surrounding the brain and spinal cord (cerebrospinal fluid) for evidence of lymphoma as well as to administer chemotherapy to the fluid around the brain. This fluid is accessed through a procedure called a lumbar puncture or “spinal tap.”

Treatment Options for Burkitt Lymphoma at Tufts Medical Center

There are several different regimens for treatment of Burkitt lymphoma. All treatments are intensive, which reflect the aggressive nature of this lymphoma. One common chemotherapy regimen is HyperCVAD (hyperfractionated) cyclophosphamide, Vincristine, doxorubicin, and dexamethasone, alternating with high-dose methotrexate and cytarabine). The monoclonal antibody rituximab may also be given depending on the clinical situation. This regimen requires staying in the hospital since the intravenous medications are given continuously. Stem cell transplantation can also be part of the treatment sequence depending on how aggressive the lymphoma is, the age and the condition of the patient.

Programs + Services

Hematologic Malignancies Program

The Hematologic Malignancies Program at Tufts Medical Center in Boston uses the latest diagnostic techniques to pinpoint your cancer type and provide you with the most effective treatment. Learn more about treatment options available for hematologic malignancies including chemotherapy, radiation therapy and more.
More information about programs and services

Doctors + Care Team

Andreas K. Klein, MD

Andreas K. Klein, MD

Title(s): Associate Chief, Division of Hematology Oncology; Director, Hematologic Malignancies Program; Assistant Director, Bone Marrow and Hematopoietic Cell Transplant Program; Chair, Tufts Health Sciences Campus Institutional Review Boards; Associate Professor, Tufts University School of Medicine
Department(s): Medicine, Hematology/Oncology
Appt. Phone: 617-636-6227
Fax #: 617-636-8538

Lymphoma, myeloma, bone marrow transplantation (BMT), immune reconstitution after BMT

View Full Profile

Kellie A. Sprague, MD

Kellie A. Sprague, MD

Title(s): Director, Bone Marrow and Stem Cell Transplant Program; Director, Adult Leukemia Program; Assistant Professor, Tufts University School of Medicine
Department(s): Medicine, Hematology/Oncology
Appt. Phone: 617-636-6227
Fax #: 617-636-8538

Bone marrow transplantation, acute and chronic leukemia, myelodysplastic syndromes, lymphoma, myeloma, myeloproliferative disorders

View Full Profile

Kenneth B. Miller, MD

Kenneth B. Miller, MD

Title(s): Associate Chief, Division of Hematology/Oncology; Professor, Tufts University School of Medicine
Department(s): Medicine, Hematology/Oncology
Appt. Phone: 617-636-2600
Fax #: 866-322-3111

Acute myelogenous leukemia (AML), myelodysplastic syndrome (MDS), lymphoma, bone marrow and stem cell transplantation

View Full Profile

Raymond L. Comenzo, MD

Raymond L. Comenzo, MD

Title(s): Director, Transfusion Services; Director, John C. Davis Myeloma and Amyloid Program; Professor, Tufts University School of Medicine
Department(s): Medicine, Pathology and Laboratory Medicine, Hematology/Oncology
Appt. Phone: 617-636-6454
Fax #: 617-636-3175

Myeloma, amyloidosis, stem cell transplant, transfusion medicine

View Full Profile

Research + Clinical Trials

A Phase I-II Trial of DA-EPOCH-R Plus Ixazomib as Frontline Therapy for Patients With MYC-aberrant Lymphoid Malignancies: The DACIPHOR Regimen

The purpose of this study is to evaluate the effects, good and bad of a new drug called ixazomib (also called MLN9708), when it is given along with a common treatment combination, called Dose-Adjusted EPOCH-R (DA-EPOCH-R, for short). This is a type of study called a phase I/II trial. In the phase I part, the dose of the study drug (ixazomib) will be adjusted (either up or down) to find the maximum (highest) dose that does not cause excessive (too many) harmful side effects. In the phase II part, this dose of ixazomib will be given at the maximum safe dose found in phase I. In both phase I and II, DA-EPOCH-R will be adjusted between cycles depending on how blood cell levels are affected between cycles. Ixazomib is considered investigational because it is not approved by the U.S. Food and Drug Administration (FDA). DA-EPOCH-R is a combination chemotherapy treatment developed over the last 14-15 years, and each of the drugs in this regimen is FDA-approved and considered part of the standard of care.
More information about research and clinical trials

Tufts Medical Center and Floating Hospital for Children have high quality care.

Quality + Safety

A world-class teaching hospital shouldn't make you feel small. At Tufts Medical Center the patient is at the center of everything that we do. This means we're committed to providing the highest quality of care in a safe, friendly environment.

Learn about our quality and safety initiatives
The City of Boston shows the harbor and buildings

200 Years of Caring for the Community

Tufts Medical Center has been taking care of Boston and the surrounding community for more than 200 years.

Read about our enduring history